Event Brief
UPDATED Jul 16, 2026 at 5:09 PM ET
Jul 16, 2026 at 10:04 AM ET
FDA approves once-daily PCSK9 pill Lipfendra
By The BriefBrief
Lipfendra, a once-daily oral PCSK9 inhibitor, received FDA approval after cutting LDL by about 56% to 60% with statins.
WHO: FDA
WHAT: FDA approval of Lipfendra, a once-daily oral PCSK9 inhibitor shown to reduce LDL cholesterol by roughly 56% to 60% with statins.
WHEN: Jul 16, 2026 at 9:35 AM ET
WHERE: USA
WHY: The FDA approved Lipfendra after clinical results showed it reduced LDL cholesterol by roughly 56% to 60% when combined with statins.
Reporting from 3 identified publishers across this event arc.
View all 3 publishers
Publishers represented across this event arc
These publishers contributed reporting to the broader event history. Not every source addresses the specific development described above.
How this brief is built: The BriefBrief correlates multiple sources into one evolving event brief, updated as new facts emerge.
Passenger boat sinks off Selayar island, 1 dead
Asia-Pacific
Jul 16, 2026 at 10:05 AM ET
Report finds ICE officers’ use of force is rising
Ice
Jul 16, 2026 at 10:04 AM ET
Todd Blanche’s confirmation hearing exchanges draw scrutiny
Todd Blanche
Jul 16, 2026 at 10:04 AM ET
Mullin says Trump ended ICE traffic stops due to TV friends
Ice
Jul 16, 2026 at 10:04 AM ET
Page 12721 of 21434
Same format. Every time.
Continue reading — sign in or create a free account with
